Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Immix Biopharma, Inc.
< Previous
1
2
Next >
Immix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece)
August 16, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting
July 25, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial
July 17, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
July 10, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial
June 26, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors
June 22, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors
June 20, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors
June 16, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program
June 14, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors
June 12, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site
May 26, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
May 04, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab
May 03, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
April 26, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting
April 04, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells
March 31, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Nexcella, an Immix Biopharma Subsidiary, Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment
March 23, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank
March 10, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14
March 06, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Subsidiary Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S.
February 15, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Subsidiary Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting
February 09, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer
February 07, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
January 13, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached
January 06, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting
December 28, 2022
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
December 20, 2022
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors
December 19, 2022
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)
December 14, 2022
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
December 13, 2022
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing
December 12, 2022
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Tickers
IMMX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.